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Summary
Atrial fibrillation (AF) usually develops within the
first 72 h following cardiac surgery, and is often self-
limiting. Within 48 h of acute onset of symptoms,
approximately 50% of patients spontaneously convert to
normal sinus rhythm. Thus, the relative risks and benefits
of therapy must be carefully considered. The etiology of
AF following cardiac surgery is similar to that in non-
surgical patients except that pericardial inflammation and
increased adrenergic tone play an increasingly important
role. Further, AF after surgery may be associated with
transient risk factors that resolve as the patient moves
out from surgery, and the condition is less likely to
recur compared with AF arising in other circumstances.
Immediate heart rate control is important in preventing
ischemia, tachycardia-induced cardiomyopathy, and left
ventricular dilatation.
At our institution, amiodarone is frequently used as
a first-line drug for treating AF after cardiac surgery.
Inconsistent prescribing practices, variable dosage regi-
mens, and a lack of consensus regarding the appropri-
ate use of amiodarone prompted the need for develop-
ing practice guidelines. Multidisciplinary collaboration
between the departments of cardiac surgery, pharmacy,
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and anesthesiology led to the development of a proto-
col for postoperative AF. We review the clinical evi-
dence from published trials and discuss our guidelines,
defining amiodarone use for AF in the cardiac surgery
setting.
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Introduction
Atrial fibrillation (AF), the most common arrhyth-
mia following cardiac surgery, occurs in 15–40% of
patients during the early postoperative period after coro-
nary artery bypass graft (CABG) surgery, 37–50% after
valve surgery, and up to 60% after a CABG plus valve
procedure.1,2 Postoperative AF increases the risk for
stroke and other complications that can prolong hospi-
talization and increase health care costs.2–4
Historically, strategies to restore and maintain nor-
mal sinus rhythm have been presumed to provide better
cardiovascular outcomes than regimens to control only
the ventricular heart rate. Antiarrythmic drugs including
quinidine, procainamide, propafenone, flecainide, ibu-
tilide, dofetilide, sotalol, and amiodarone have com-
prised the mainstay of therapy. The primary concern
with antiarrythmic drugs is the possibility of proarry-
thmic complications including ventricular arrhythmia,
QT-interval prolongation, and life-threatening torsades
de pointes.
Amiodarone
Amiodarone slows AV nodal conduction and prolongs
AV nodal refractoriness through its calcium-channel
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blocking and beta-blocking properties. In recent years,
amiodarone has been the drug most frequently used
for atrial stabilization because it rarely causes pro-
arrhythmic complications. In a meta-analysis of double-
blind, placebo-controlled trials that included patients
with underlying heart failure or myocardial infarction,
there were no cases of torsade de pointes in 738 patients
receiving amiodarone therapy for at least 1 year.5 How-
ever, amiodarone is associated with noncardiac toxicity
including pulmonary, hepatic, thyroid, and neurologic
side-effects.5 Intravenous (IV) administration can cause
hypotension, bradycardia, and thrombophlebitis.
Prevention of AF in patients scheduled to undergo
cardiac surgery is a reasonable goal, and trials have
evaluated the effectiveness of prophylactic amiodarone
therapy.6,7 The largest trial in cardiac surgery patients
is the Prophylactic Oral Amiodarone for the Prevention
of Arrythmias that Begin Early After Revascularization,
(PAPABEAR) Valve Replacement, or Repair study.7 In
this randomized, double-blind, placebo-controlled trial,
601 patients undergoing CABG surgery, valve replace-
ment/repair, or both, were randomized to receive oral
amiodarone or placebo, starting 6 days prior to surgery
and continuing for 6 days postoperatively. More than
half the patients in each treatment group also received
preoperative beta-blockers. Amiodarone therapy was
associated with a 52% relative risk reduction in AF
compared with placebo (16.1% versus 29.5%; p<0.001),
and sustained postoperative ventricular tachyarrythmias
occurred less frequently with amiodarone than placebo
(0.3% versus 2.6%; p = 0.04). While prophylactic amio-
darone has been shown to be effective, its advantage over
prophylactic beta-blocker therapy has not been demon-
strated. A meta-analysis of 52 randomized trials of beta-
blockers, sotalol, or amiodarone, showed that the three
drug treatments each prevented AF with the following
odds ratios (OR): beta-blockers, 0.39 (95% CI, 0.28 to
0.52); sotalol, 0.35 (95% CI, 0.26 to 0.49); and amio-
darone, 0.48 (95% CI, 0.37 to 0.61).8 Thus, the three
drugs appear to have similar efficacy for preventing AF
in patients undergoing cardiac surgery.
Large-scale placebo controlled trials have not specif-
ically focused on postoperative medical cardioversion,
and well-designed trials evaluating amiodarone for treat-
ing postsurgical AF are lacking. Two randomized tri-
als assessed the efficacy of amiodarone compared with
propafenone in reversing AF after cardiac surgery.9,10 In
the first study, 84 patients with sustained AF were ran-
domized to receive IV amiodarone or IV propafenone.
Within 24 h, 38 of 46 patients (82.6%) given amio-
darone and 26 of 38 patients (68.4%) given propafenone
converted to sinus rhythm, the difference was not signif-
icant. Side effects were more common with propafenone
treatment, although the difference did not achieve statis-
tical significance. Mean blood pressure was not signifi-
cantly influenced by either drug. In the second study,10
forty patients undergoing cardiac surgery either received
propafenone IV or amiodarone IV for treatment of post-
surgical AF. Sinus rhythm was restored in 12 of 18 (67%)
propafenone patients and in 17 of 22 (77%) amiodarone
patients, the difference was not statistically significant.
Beta-blockers and Calcium-channel Blockers
Rate control strategies target the ventricular response
without attempting to convert AF to normal sinus rhythm.
Drugs for rate control have included digoxin, beta-
blockers, and calcium-channel blockers. Clinical trials
with digoxin are limited by lack of randomization, small
sample size and postoperative withdrawal of beta-blocker
therapy. The onset of action of digoxin can take from
4 to 6 h, and the drug is relatively ineffective in high
catecholamine states that exist after cardiac surgery.
Beta-blockers are generally accepted as the mainstay
of therapy for ventricular rate control in patients with
AF. Beta-blockers prolong AV nodal conduction time,
antagonize the cardiac effects of catecholamine through
their sympatholytic properties, and offer additional ben-
efits in the setting of ischemia or infarction. The drugs
promote atrial stabilization, and reportedly decrease post-
operative mortality.11,12 The 2005 American College
of Chest Physicians guidelines for the Prevention and
Management of Postoperative Atrial Fibrillation after
Cardiac Surgery recommends beta-blockers as first-line
therapy for patients with AF who do not require urgent
cardioversion.13
Many patients with coronary artery disease receive
beta-blockers preoperatively, and their withdrawal has
been shown to increase the risk of postoperative AF,12,13
emphasizing the need to continue beta-blocker therapy
postoperatively. One randomized, controlled trial com-
pared the efficacy of esmolol with that of diltiazem in
the management of 30 patients with postoperative AF
following cardiac surgery.14 Esmolol was as effective as
diltiazem for ventricular rate control at 24 h in patients
who did not convert to sinus rhythm. Limitations of the
study include the small sample size and differences in
ancillary medications between the groups. The largest
trial evaluating the effectiveness of beta-blocker therapy
in postoperative AF is the Beta-Blocker Length of Stay
(BLOS) study.15 In this double-blind, placebo-controlled
randomized trial of 1,000 patients undergoing cardiac
surgery, metoprolol was associated with a 20% relative
risk reduction in AF (31% versus 39%; p = 0.01).
Among calcium-channel blockers, both verapamil and
diltiazem are effective for heart rate control in patients
with AF. The drugs prolong AV nodal refractory period
and slow AV nodal conduction through blockade of
the L-type calcium channel. Concerns with verapamil
relate to the drug’s negative inotropic effect, especially
in patients with left ventricular dysfunction. In addition,
verapamil is a potent peripheral vasodilator that may pro-
duce severe hypotension when given IV. In comparison,
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diltiazem has little peripheral vasodilating effects, less
negative inotropic effects, and causes less hypotension
than verapamil. In a large study evaluating the efficacy
and safety of IV diltiazem for AF, the overall response
rate was 94% with a maximal decrease in heart rate
observed at 4.3 min from the start of infusion.16 There
were no cases of symptomatic hypotension, and the mean
decrease in systolic blood pressure was 8 mmHg.
Beta-blocker versus Calcium-channel Blockers
Well-designed randomized trials comparing calcium-
channel blockers with beta-blocker therapy for postsur-
gical AF are lacking. Findings from available studies are
difficult to interpret because of different study designs
and exclusion of patients with congestive heart failure,
decreased left ventricular function and conduction abnor-
malities.
One randomized placebo-controlled trial comparing
diltiazem and propranolol showed that diltiazem was not
effective while propranolol was associated with a signifi-
cant reduction in AF following CABG surgery.17 Mooss
et al.14 conducted a prospective, open-label, randomized
study of IV esmolol versus IV diltiazem in patients with
postoperative AF. The findings showed a higher rate of
conversion of AF at 6 h with esmolol, but there was
no difference in conversion rates at 24 h. This study is
marked by limitations, notably 50% of patients in the
diltiazem group had their beta-blocker therapy discon-
tinued.
Rate versus Rhythm Control in Light of New
Evidence
There is limited data supporting a strategy for rhythm
control versus rate control in the postcardiac surgery
patient. Large randomized trials have primarily included
patients with persistent AF in the nonsurgical setting.
In the Pharmacological Intervention in Atrial Fibril-
lation (PIAF) trial, 252 patients with persistent symp-
tomatic AF of 7–360 days’ duration were randomized to
rate control using oral diltiazem or rhythm control with
oral amiodarone.18 Both groups showed symptomatic
improvement over time and the quality of life scores
were similar. Rhythm control patients however, required
more hospitalizations related to drug side effects (69%
versus 24%; p = 0.001).
The largest randomized trial that tested rate versus
rhythm control in patients with AF is the Atrial Fibril-
lation Follow-up Investigation of Rhythm Management
(AFFIRM) trial.19 The study included 4,060 patients with
persistent AF who were at least 65 years of age, or
who had at least one risk factor for stroke or death.
The mean follow-up time was 3.5 years with a maxi-
mum of 6 years. Patients were randomized to rate control
using oral digoxin, beta-blocker, and/or calcium-channel
blockers, anticoagulation with warfarin; or to rhythm
control therapy. The most frequently used antiarrythmic
drugs were amiodarone and sotalol; warfarin use was
left to the discretion of the investigator. Rate control
was achieved in 80% of patients receiving rate con-
trol while in the rhythm control arm 60% of patients
achieved sinus rhythm; neither strategy was found supe-
rior in the primary outcome of total mortality or in the
secondary composite end point of total mortality, stroke,
major bleeding, or cardiac arrest. After adjustment for
variables such as age and ejection fraction, the risk of
adverse drug effects and death was significantly lower in
the rate control group. The incidence of ischemic strokes
was similar between the groups and strongly related to
the lack of or subtherapeutic anticoagulation, highlight-
ing the need for continued and adequate anticoagulation
regardless of the strategy used. Quality of life scores
were also similar in both groups. Thus, the presumed
benefits of rhythm control over rate control strategies
were not confirmed in the study.
Thus, randomized trials comparing rate with rhythm
control strategies have shown no distinct advantage
to either strategy in various primary endpoints, which
ranged from cardiovascular events and quality of life to
total mortality. Complications related to arrythmia, dis-
continuation of therapy, or hospitalization secondary to
drug toxicity occurred more often with rhythm control. A
recently published meta-analysis of AF trials shows sig-
nificant risk reduction for the combined endpoint of all
cause death and thromboembolic stroke with rate-control
versus rhythm-control (p = 0.02).20
It is important to note that randomized trials show-
ing lack of advantage of rhythm versus rate control were
conducted outside the setting of recent heart surgery, and
primarily included patients with persistent AF in whom
long-term treatment was warranted. The AF that devel-
ops after cardiac surgery is often self-limiting, associated
with transient risk factors that resolve as the patient
moves out from surgery, and less likely to recur com-
pared with AF arising in other circumstances. Given the
high spontaneous conversion rate, patients may revert to
sinus rhythm simply with heart rate control and obser-
vation. Thus, the decision of rate versus rhythm control
needs to be determined for each patient based on indi-
vidual characteristics.
University of Michigan Clinical Practice
Guidelines
Figure 1 summarizes our proposed guidelines for man-
aging AF following cardiac surgery. The protocol has
two pathways based on the presenting heart rate. We rec-
ommended rate control with beta-blockers as first-line
therapy. Recently published guidelines by the Ameri-
can College of Chest Physicians for the Prevention and
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Management and Treatment of Atrial
Fibrillation After Cardiac Surgery
Heart rate ≤ 110 Heart rate > 110
If Currently on beta-blocker: If Ejection fraction > 20 consider:
If Ejection fraction < 20 consider:
If BP < 85 or 10−30mm Hg below baseline:
Increase dose or give dose early 1. Metoprolol: 5−10 mg IV: may repeat to total of 15 mg
1. Amiodarone bolus or load as stated above
2. Increase beta blocker
2. If in ICU: esmolol infusion 50−100 mg/min
3. Diltiazem: 5−10 mg IV (may repeat to total of 20 mg)
5. Diltiazem infusion: 5 mg/hr, maximum 15 mg/hr (titrate for SBP > 90 mm Hg)
Otherwise consider: metoprolol 5−10 mg IV
May start amiodarone IV or PO 6. Amiodarone 150 mg IV bolus (may repeat)
7. Amiodarone load:
    IV: 1 mg/min x 6 hr, then 0.5 mg/min x 18 hr, then 200 mg PO daily.
    PO: 600 mg PO TID x 9 doses, then 200 mg PO daily.
FIG. 1 Management and treatment of atrial fibrillation after cardiac surgery. BP = blood pressure; IV = intravenous;
PO = oral; TID = 3times daily; SBP = systolic blood pressure; ICU = intensive care unit.
Management of Postoperative AF after cardiac surgery,
supports this decision.13,21,22 Beta-blockers remain a
good initial choice because of their ability to counter-
act the hyperadrenergic state after surgery. We recom-
mended calcium-channel blockers as second-line agents,
reserving amiodarone for unstable or recalcitrant AF.
For immediate rate control in hemodynamically stable
patients, we recommended IV metoprolol, converting to
the oral route as soon as possible. In the intensive care
unit, an esmolol infusion could be started and titrated
closely. Patients previously maintained on beta-blockers
were to continue with the therapy after surgery. Among
calcium-channel blockers, we selected diltiazem as the
preferred drug because of its more favorable hemody-
namic properties. After an IV bolus of diltiazem, reduc-
tion in ventricular response occurs rapidly. If neces-
sary, a continuous infusion of diltiazem could be started,
dosages are shown in Figure 1. Patients refractory to
monotherapy with metoprolol or diltiazem could receive
both drugs concomitantly.
For patients with recalcitrant AF, we recommended
treatment with amiodarone. Amiodarone could be initi-
ated IV for patients unable to take oral therapy, and tran-
sitioned to the oral route when tolerated. For patients able
to tolerate oral therapy, oral loading of amiodarone may
restore sinus rhythm and continued therapy is effective
for maintaining sinus rhythm. Amiodarone was also the
preferred therapy for patients with AF who were hemo-
dynamically stable but had low blood pressure, based
on evidence showing its safety in this situation.9,23 The
IV beta-blockers or calcium-channel blockers in such
patients can cause further hypotension. For patients with
depressed left ventricular function and those with ejec-
tion fraction < 20%, amiodarone was recommended as
first-line therapy based on its lack of negative inotropic
effects and low proarrythmia potential.24 Although some
clinicians recommend against the use of beta-blockers
in patients with low ejection fractions it must be noted,
however, that the drugs have provided survival benefit
in nonsurgical patients with heart failure.13
Conclusions
The proarrythmic potential of antiarrythmic drugs is
critical in the setting of open heart surgery, highlight-
ing the need for individualization of therapy. Multidisci-
plinary collaboration between the departments of cardiac
surgery, pharmacy, and anesthesiology led to the devel-
opment of practice guidelines for managing AF after
cardiac surgery. The guidelines emphasized rate control
first with beta-blockers, then calcium-channel blockers,
reserving amiodarone for unstable or recalcitrant AF. In
patients with relatively low blood pressure, depressed
left ventricular function, or ejection fraction less than
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20%, we recommended the use amiodarone as the first-
line therapy. As new information, new drugs, and results
from new studies become available, we plan to update
our current guidelines.
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